# N4 Pharma successful Nuvec double siRNA testing

- Link: https://www.directorstalkinterviews.com/n4-pharma-successful-nuvec-double-sirna-testing/4121084904
- Published: 2022-10-04T07:25:52+01:00
- Author: Amilia Stone

**N4 Pharma Plc** (LON:N4P), the specialist pharmaceutical company developing Nuvec
^(®), a novel delivery system for cancer treatments and vaccines, has announced 
successful _in vitro_ testing of Nuvec^(®) loaded with two small interfering RNA(
siRNA) probes.

On 14 September 2022, the Company announced a strategic update highlighting its 
intention to focus its further development work on multiple loaded siRNA on Nuvec
^(®).

The Company has now completed initial _in vitro_ testing of Nuvec® loaded with two
generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone
Lysine Methyltransferase 2) at the same time. The siRNA probes were loaded onto 
Nuvec^(®) in equal amounts, at a concentration previously shown to be active. Testing
demonstrated that both siRNA probes when loaded onto Nuvec^(®) were able to significantly
silence their respective targets.

> **Nigel Theobald, Chief Executive Officer of N4 Pharma, commented**:
> “Showing that Nuvec^(®) loaded with two generic siRNA probes still achieves significant
> silencing of their respective genes is validation for us to now begin the further
> work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer
> model.
> “Achieving the initial successful testing of Nuvec^(®) with the generic GFP and
> EHMT-2 siRNA will also allow us to commence commercial outreach discussions which
> will only be further strengthened by the results from the new work we are undertaking.”

Share on:
